Category: St. Jude Medical
Occlutech says a U.K. court invalidated a patent held by St. Jude Medical covering atrial septal occluder technology.
European approval of next-generation ablation catheter further strengthens St. Jude Medical's fast-growing ablation technology portfolio.
Minnesota medtech giant St. Jude Medical touts 1st use of its FlexAbility ablation catheter after landing approval from European regulators.
European regulators put their stamp of approval on St. Jude Medical's (NYSE:STJ) new FlexAbility ablation catheter, paving the way to 1st use of the next-generation device.
A Danish study of St. Jude Medical's recalled Riata and Riata ST defibrillator leads suggests that the externalization problem that led to the recall worsens over time and is linked to "electrical abnormalities."
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B
St. Jude Medical's 2nd-quarter results, including a 2% gain for its implantable cardiac defibrillator business, could signal a rebound for the ICD sector overall, according to Leerink Partners.
St. Jude Medical enters the spinal pain treatment arena with the $200 million cash acquisition of NeuroTherm and its radiofrequency ablation technology.
Minnesota-based medtech giant St. Jude Medical (NYSE:STJ) is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.